Breast Cancer

Pemetrexed disodium (Alimta, LY231514) is a novel, multitargeted antifolate that inhibits thymidylate synthase, dihydrofolate reductase, and glycinamide ribonucleotide formyl transferase. This agent is broadly active in a wide

In recent years, the clinical application of paclitaxel (Taxol), docetaxel (Taxotere), vinorelbine (Navelbine), and trastuzumab (Herceptin) has improved the management of advanced breast cancer. With the introduction of

Docetaxel (Taxotere) and gemcitabine (Gemzar) are active agents against breast cancer. Several phase I studies evaluated different schedules of their combination and clearly demonstrated that docetaxel and gemcitabine can

In a single-center, open, phase II trial, we assessed the toxicity and activity of a triple combination therapy-doxorubicin at 30 mg/m2 (day 1), paclitaxel (Taxol) at 135 mg/m2 (day 2), and gemcitabine (Gemzar) at 2,500 mg/m2

In a phase II trial, 29 patients with anthracycline-pretreated or anthracycline-resistant metastatic breast cancer in whom anthracycline-containing first- or second-line chemotherapy failed received combination paclitaxel

A phase II trial evaluated the effectiveness and toxicity of combination paclitaxel (Taxol), gemcitabine (Gemzar), and trastuzumab (Herceptin) as first-line therapy for patients with newly diagnosed HER2-overexpressing

The goal of this activity is to clarify challenging treatment issues of HER2+ breast cancer including incorporation of predictive and prognostic biomarker tests and evidence-based data into practice when determining individualized strategies that improve patient survival and quality of life.

Capecitabine (Xeloda) is the first orally available fluoropyrimidine approved for use in patients with cancer. It was initially approved for use in metastatic breast cancer, but significant data also support its use in the management

UFT and leucovorin (Orzel) is a combination of tegafur and uracil in a molar ratio of 1:4. Tegafur, a prodrug of 5-fluorouracil (5-FU), is converted to 5-FU by the hepatic cytochrome P450 pathway, whereas uracil enhances the

New treatment strategies for advanced breast cancer have focused on both the development of new molecular targets in breast cancer cells, as well as improving the therapeutic index of presently available therapy. The

WASHINGTON-Inositol hexa-phosphate (IP6) has shown antitumor effects in vitro and in animal models and may be ready for clinical trials in humans, said Ivana Vucenik, PhD, associate professor of medical and research technology, University of Maryland School of Medicine, Baltimore. She presented her study results at the Susan G. Komen Breast Cancer Foundation grants conference "Reaching for the Cure."

BETHESDA, Md-Adjuvant therapy should be offered as an option to node-negative breast cancer patients, even those with tumors smaller than 1 cm, said Bernard Fisher, MD, scientific director of the National Surgical Adjuvant Breast and Bowel Project (NSABP).

There is no evidence that a high-fat diet predisposes older women to breast cancer, report researchers from Harvard Medical School. It has long been thought that dietary fat can increase production of sex hormones, including estrogen, and

BETHESDA, Md-High-risk breast cancer patients receiving intermediate- or high-dose consolidation chemotherapy after CAF achieved overall survival that is "better than any other experience within the CALGB," William Peters, MD, PhD, said at the NIH Consensus Conference on Adjuvant Therapy for Breast Cancer. He gave an update of CALGB 9082/SWOG 9114/NCIC MA-13.

NEW YORK-Letrozole (Femara) was found to be superior to tamoxifen (Nolvadex) in the largest study ever conducted of endocrine therapy in advanced breast cancer, Matthew J. Ellis, MD, PhD, clinical director of the Duke University Breast Cancer Program, said at the XVIII Chemotherapy Foundation Symposium. Median time to progression was 41 weeks for letrozole vs 26 weeks for tamoxifen (P = .0001), he said.

WASHINGTON-Umbilical cord blood cells alone have no cytotoxic properties, but studies show that when activated with interleukin-2 (IL-2), they may have some therapeutic effects against breast cancer, said Shantaram S. Joshi, PhD, associate professor of cell biology and anatomy, University of Nebraska Medical Center.

SAN ANTONIO-Results of a large phase III trial show that combining oral capecitabine (Xeloda) with docetaxel (Taxotere) significantly improved overall survival, time to disease progression, and response rates over docetaxel alone in women with anthracycline-resistant metastatic breast cancer.

BETHESDA, Md-Seconding the advice of a Food and Drug Administration review team, the Oncologic Drugs Advisory Committee (ODAC) has recommended that the FDA approve Femara tablets (letrozole, Novartis) as first-line therapy in postmenopausal women with advanced breast cancer.

CHICAGO-Unless relative value reimbursement units for mammography services rise by a factor of three, the US health care system will not be able to keep up with the expected demand for diagnostic and screening examinations for breast cancer, a panel of radiologists said at the annual meeting of the Radiological Society of North America (RSNA).

BETHESDA, Md-The aggregate benefit of adjuvant systemic chemotherapy is "greater than many would think," reflecting "real and substantial" progress, Gabriel N. Hortobagyi, MD, professor and chairman of Breast Medical Oncology, M.D. Anderson Cancer Center, said at the NIH Consensus Conference on Adjuvant Therapy for Breast Cancer.

PHILADELPHIA-The Women’s Intervention Nutrition Study (WINS) has completed accrual, with some 2,400 women enrolled to date. The study, an NCI-funded, randomized, multicenter national trial begun in 1993, is testing the hypothesis that dietary fat intake reduction as an adjuvant to standard breast cancer therapy will reduce disease recurrence and increase survival in women with localized breast cancer.

BETHESDA, Md-Interim analysis of the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-28 trial has shown no additional benefit to adding four cycles of paclitaxel (Taxol) after the standard doxorubicin (Adria-mycin)/cyclophosphamide (AC) regimen in the adjuvant treatment of node-positive breast cancer.

The care of a pregnant breast cancer patient is a challenging clinical situation that historically has placed the welfare of the mother in conflict with that of the fetus. For the woman in this situation, the emotions usually

The care of a pregnant breast cancer patient is a challenging clinical situation that historically has placed the welfare of the mother in conflict with that of the fetus. For the woman in this situation, the emotions usually

The care of a pregnant breast cancer patient is a challenging clinical situation that historically has placed the welfare of the mother in conflict with that of the fetus. For the woman in this situation, the emotions usually